Paper39698262
Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.
Mehta D and 4 others. ACS Pharmacol Transl Sci, 2024. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies. Papers, record 39698262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39698262
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References153
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25519700 | MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. | Mol Cancer Ther | 2015 | https://conductscience.org/library/papers/25519700 | PubMed |
| 2 | 21482669 | mTORC2 is required for proliferation and survival of TSC2-null cells. | Mol Cell Biol | 2011 | https://conductscience.org/library/papers/21482669 | PubMed |
| 3 | 19861459 | MYC-induced cancer cell energy metabolism and therapeutic opportunities. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19861459 | PubMed |
| 4 | 26003166 | The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. | Oncotarget | 2015 | https://conductscience.org/library/papers/26003166 | PubMed |
| 5 | 26321679 | Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. | Cell | 2015 | https://conductscience.org/library/papers/26321679 | PubMed |
| 6 | 26170313 | Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. | Proc Natl Acad Sci U S A | 2015 | https://conductscience.org/library/papers/26170313 | PubMed |
| 7 | 21430067 | mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. | Cancer Res | 2011 | https://conductscience.org/library/papers/21430067 | PubMed |
| 8 | 23636326 | mTOR kinase structure, mechanism and regulation. | Nature | 2013 | https://conductscience.org/library/papers/23636326 | PubMed |
| 9 | 22500797 | mTOR signaling in growth control and disease. | Cell | 2012 | https://conductscience.org/library/papers/22500797 | PubMed |
| 10 | 21339740 | Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis. | Oncogene | 2011 | https://conductscience.org/library/papers/21339740 | PubMed |
| 11 | 27713169 | A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. | Oncotarget | 2016 | https://conductscience.org/library/papers/27713169 | PubMed |
| 12 | 10691731 | Loss of PTEN facilitates HIF-1-mediated gene expression. | Genes Dev | 2000 | https://conductscience.org/library/papers/10691731 | PubMed |
| 13 | 27174914 | p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma. | Oncotarget | 2016 | https://conductscience.org/library/papers/27174914 | PubMed |
| 14 | 18042549 | Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. | J Biol Chem | 2008 | https://conductscience.org/library/papers/18042549 | PubMed |
| 15 | 24140020 | mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. | Cell Metab | 2013 | https://conductscience.org/library/papers/24140020 | PubMed |
| 16 | 22067397 | Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22067397 | PubMed |
| 17 | 19963096 | Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. | Semin Oncol | 2009 | https://conductscience.org/library/papers/19963096 | PubMed |
| 18 | 18089801 | mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. | Cancer Res | 2007 | https://conductscience.org/library/papers/18089801 | PubMed |
| 19 | 16569767 | Differential regulation of T-cell growth by IL-2 and IL-15. | Blood | 2006 | https://conductscience.org/library/papers/16569767 | PubMed |
| 20 | 26299952 | Toward rapamycin analog (rapalog)-based precision cancer therapy. | Acta Pharmacol Sin | 2015 | https://conductscience.org/library/papers/26299952 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42619501 | Astragaloside IV and rapamycin co-loaded bone marrow mesenchymal stem cell-derived exosome nanocarriers for targeted modulation of the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. | Nanomedicine (Lond) | 2026 | https://conductscience.org/library/papers/42619501 | PubMed |
| 42305219 | Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity. | ACS Med Chem Lett | 2026 | https://conductscience.org/library/papers/42305219 | PubMed |
| 42168745 | Polyploidy and Senescence of Cancer Cells: Impact of Cell Fusion. | Adv Exp Med Biol | 2026 | https://conductscience.org/library/papers/42168745 | PubMed |
| 42080921 | Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study. | Virchows Arch | 2026 | https://conductscience.org/library/papers/42080921 | PubMed |
| 41958649 | P62 in colorectal cancer: from inflammation suppression to cancer promotion. | Front Immunol | 2026 | https://conductscience.org/library/papers/41958649 | PubMed |
| 41424791 | The PI3K/AKT/mTOR pathway in scar remodeling and keloid formation: mechanisms and therapeutic perspectives. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41424791 | PubMed |
| 41384305 | mTOR in radiotherapy of lung cancer: Mechanisms of radiation resistance and therapeutic implications (Review). | Int J Oncol | 2026 | https://conductscience.org/library/papers/41384305 | PubMed |
| 41340489 | Androsin alleviates colorectal cancer by inhibiting the PI3K/Akt-centered signaling pathway. | Korean J Physiol Pharmacol | 2026 | https://conductscience.org/library/papers/41340489 | PubMed |
| 41321380 | Epithelial-mesenchymal dynamics in cancer: Role of signalling pathways, stromal interactions and natural therapies. | ADMET DMPK | 2025 | https://conductscience.org/library/papers/41321380 | PubMed |
| 41230168 | Icariside II attenuates renal fibrosis through mTOR signaling modulation: an integrated approach combining network pharmacology, molecular dynamics, and in vitro validation. | Transl Androl Urol | 2025 | https://conductscience.org/library/papers/41230168 | PubMed |
| 41201553 | Molecular co-alteration patterns of RICTOR-mutant metastatic lung adenocarcinomas: a single-center cohort study. | Virchows Arch | 2026 | https://conductscience.org/library/papers/41201553 | PubMed |
| 41188991 | Engineered immune-driven theranostics for clinical cardiology. | Mil Med Res | 2025 | https://conductscience.org/library/papers/41188991 | PubMed |
| 41181393 | Circadian system and aging: where both times interact. | Front Aging | 2025 | https://conductscience.org/library/papers/41181393 | PubMed |
| 40996472 | Synthesis of CNP-SAR405 delivery system for improved therapeutics anticancer activity using A549 human lung cancer cell lines. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/40996472 | PubMed |
| 40671967 | A comprehensive analysis of the relationship between inflammasomes and autophagy in human tumors: Recent developments. | J Cell Commun Signal | 2025 | https://conductscience.org/library/papers/40671967 | PubMed |
| 40148397 | An in- vitro measurement for the toxicity of peptides inhibit hexokinase II in breast cancer cell lines. | Sci Rep | 2025 | https://conductscience.org/library/papers/40148397 | PubMed |
| 40092733 | IL-11 promotes Ang II-induced autophagy inhibition and mitochondrial dysfunction in atrial fibroblasts. | Open Life Sci | 2025 | https://conductscience.org/library/papers/40092733 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39698262
GET https://conductscience.org/api/papers/v1/39698262/references?page=2